Background {#Sec1}
==========

Calcific uremic arteriolopathy (CUA), also called calciphylaxis, is a rare but devastating disease involving patients with end stage renal disease (ESRD). CUA causes painful skin lesions that evolve to ulcerative lesions at risk of superinfection and sepsis \[[@CR1]\], with a poor prognosis. One year survival rates vary between 45 to 55% \[[@CR2]--[@CR4]\]. CUA management lacks strong recommendations \[[@CR5]\] and therefore is heterogeneous. Reported risk factors of CUA are female sex, obesity, diabetes mellitus, vitamin K antagonists (VKA) and ESRD \[[@CR6]\]. Dysregulation of calcium-phosphate metabolism also participates to its development. Histopathological findings of skin lesions mostly associate thromboses and vessel calcifications \[[@CR7]\]. We decided to conduct the first study on CUA in the French population. Our main objective was to describe diagnosis management, treatment and outcome of CUA in ESRD and stage 4--5 CKD patients. Secondary objectives were to analyze risk factors of developing calciphylaxis and influencing patient survival in the dialyzed cohort.

Materials and methods {#Sec2}
=====================

Study patients {#Sec3}
--------------

We first conducted a retrospective cohort study and secondly a case control analysis. The nephrologists from Western France were asked to report their patients diagnosed for CUA. Patients were also identified by searching the MEDIAL dialysis regional data base. Inclusion and non-inclusion criteria checking and collection of the data in the medical records were performed by the investigators in the center of care of each case.

Hayashi \[[@CR8]\] criteria were used for diagnosis: chronic hemodialysis or estimated Glomerular Filtration Rate (eGFR) below 15 mL/min/1.73m^2^, more than two painful non-treatable skin ulcers with concomitant painful purpura and localization of skin ulcers on the trunk, extremities or penis with concomitant painful purpura. Typical histopathological findings (necrosis and ulceration of the skin with calcification of the tunica media and internal elastic membrane of small to medium-sized arterioles of dermis and subcutaneous fat) can replace a clinical feature.

Inclusion criteria were: CUA according to Hayashi criteria, onset of cutaneous lesions between 1st January 2006 and 31th December 2016, patients \> 18 yo. Patients with eGFR between 15 and 30 mL/min/1.73m^2^ (CKD EPI formula) (the serum creatinine at onset of CUA was considered) were also included if all other inclusion criteria were met. CUA was eliminated if a differential diagnosis seemed more likely or was confirmed by skin biopsy, or in case of severe atherosclerotic vascular disease in the wound area. CUA patients under hemodialysis or peritoneal dialysis at onset of CUA lesions were assigned to the dialysis group, while the others to the non dialysis group.

Controls selection {#Sec4}
------------------

In order to explore risk factors of CUA among dialyzed patients, each CUA dialysis patient was matched with two controls identified in the REIN registry of treated ESRD in France. Matching criteria were: gender, age (± 2 years), treatment by hemodialysis in the same geographical area and at the same time of CUA diagnosis in the case. Among the potential controls for each case, two were randomly and anonymously selected. After checking the absence of diagnosis of CUA, collection of the data in the medical records of the control patients was performed by the investigator directly in the center of care of the patient.

Study data {#Sec5}
----------

The analyzed data were demographic, history of kidney disease, cardiovascular comorbidities and other previously reported risk factors of CUA. Thrombophilia was defined as acquired or congenital antithrombin/protein C/protein S deficiency, antiphospholipid syndrome, activated protein C resistance, prothrombin mutation. "Onset date" of CUA was the date where typical skin lesions were mentioned in medical records. Laboratory data at onset were recorded as well as the worst values within the 6 months before diagnosis. As intact Parathyroid hormone (iPTH) measurement kits were different between laboratories, we normalized iPTH with the upper limit of the normal range for each laboratory. Medications and dialysis parameters were recorded. For each CUA case, clinical presentation with lesion distribution defined as proximal (extremities proximal to knees and elbows, trunk, breast and penis) and/or distal (extremities distal to knees and elbows), evolution, diagnosis and treatment methods and outcomes were collected.

A written consent form was given to each patient, except for deceased patients and loss of follow-up patients. The study was approved by the ethics committee of the Nantes University Hospital. All data collected were de-identified.

Statistical analyses {#Sec6}
--------------------

Frequency of categorical variables, median and interquartile range (IQR) for non-normally distributed variables were reported. Survival curves were determined using the Kaplan-Meier method. Survival analysis using Cox models were used to determine survival predictors. In the group of CUA patients treated by dialysis, univariate conditional logistic regression analysis on matched case-controls was performed. Variables with *p* \< 0.20 were included in the multivariate logistic regression analysis. Non dialyzed CUA patients were not included in the risk factor analysis because of the lack of controls for those patients.

All analyses were performed using the SAS program (version 9.4) (SAS Institute Inc., Cary, NC). Statistical significance was set as *p* \< 0.05. The study protocol was pre-registered on [clinicaltrials.gov](http://clinicaltrials.gov) under the number NCT02854046.

Results {#Sec7}
=======

Two hundred fourteen eligible cases were identified (Fig. [1](#Fig1){ref-type="fig"}). Ninety-five patients with incomplete diagnosis criteria and 22 with a differential diagnosis were excluded ([Table S1](#MOESM1){ref-type="media"}). Eighty-nine cases of CUA were finally included, 74% diagnosed between 2013 and 2016. Fig. 1Flow chart of selection of Calcific Uremic Arteriolopathy cases

Baseline characteristics (Table [1](#Tab1){ref-type="table"}) {#Sec8}
-------------------------------------------------------------

75.3% of cases were hemodialyzed. Among the 19 patients with stage 4--5 chronic kidney disease (CKD), median eGFR was 10.3 ml/min/1.73m^2^ (IQR 8.4--13.0) and median blood urea nitrogen was 31 mmol/L (IQR 20--47). CUA patients were obese (median Body Mass Index (BMI) 31 kg/m^2^) and had a recent median weight loss of 3.5 kg. In dialyzed and non dialyzed CUA cases, the main causes of CKD were respectively diabetes-associated nephropathy (25.7 and 26.3%), hypertension-associated nephropathy (22.9 and 0%), hypertension and diabetes-associated nephropathy (15.7 and 21.1%) and glomerular nephropathy (10.0 and 26.3%). 5 CUA patients only had proven thrombophilia. Table 1Demographic data of CUA cases and the matched dialysis controlsParameterNTotal CUA casesNNon dialysis casesNDialysis casesNDialysis controls*P* ValueAge (years)8970 (63--78)1971 (58--79)7070 (64--78)14069 (63--77)Females8957 (64.0%)198 (42.1%)7049 (70.0%)14098 (70.0%)BMI (kg/m^2^)8931.0 (25.3--37.3)1934.6 (28.6--39.2)7030.7 (24.5--37.1)13725.1 (21.6--28.6)\< 0.001 Overweight (BMI 25--30 kg/m2)20 (22.5%)6 (31.6%)14 (20.0%)40 (29.2%) Obesity (BMI 30--40 kg/m2)33 (37.1%)10 (52.6%)23 (32.9%)26 (19.0%) Severe obesity (BMI \> 40 kg/m2)16 (18.0%)3 (15.8%)13 (18.6%)3 (2.2%)Loss of weight within 6 months before diagnosis (kg)823.5 (0.5--7.0)167.0 (3.0--15.9)663.0 (0.0--6.0)1340.0 (−1.1--1.5)\< 0.001CKD stage (eGFR)891970140 CKD Stage 4 (15--30 mL/min/1.73m^2^)4 (4.5%)4 (21.0%) CKD Stage 5 (\< 15 mL/min/1.73m^2^)15 (16.8%)15 (70.0%) CKD stage 5 under Hemodialysis67 (75.3%)67 (95.7%)140 (100%) CKD stage 5 under PD3 (3.4%)3 (4.2%)CAD8941 (46.1%)196 (31.6%)7035 (50.0%)14050 (35.7%)0.047Heart failure8951 (57.3%)1911 (57.9%)7040 (57.1%)14034 (24.3%)\< 0.001Stroke8914 (15.7%)193 (15.8%)7011 (15.7%)14025 (17.9%)0.70PAD with symptoms8935 (39.3%)194 (21.1%)7031 (44.3%)14040 (28.6%)0.02Diabetes mellitus8960 (67.4%)1917 (89.5%)7043 (61.4%)14056 (40.0%)0.003Arterial Hypertension8985 (95.5%)1918 (94.7%)7067 (95.7%)140121 (86.4%)0.04Hypercholesterolemia8952 (58.4%)1911 (57.9%)7041 (58.6%)14087 (62.1%)0.61History of smoking8920 (22.5%)196 (31.6%)7014 (20.0%)13723 (16.8%)0.57Parathyroidectomy894 (4.5%)190 (0.0%)704 (5.7%)1408 (5.71%)1History of pathologic fracture8919 (21.3%)192 (10.5%)7017 (24.3%)14017 (12.1%)0.02Progressive cancer899 (10.1%)192 (10.5%)707 (10.0%)14014 (10.0%)1Hepatobiliary disease8915 (16.9%)192 (10.5%)7013 (18.6%)14016 (11.4%)0.16Chronic alcoholism897 (7.9%)192 (10.5%)705 (7.1%)1406 (4.3%)0.51Connective tissue disease897 (7.9%)192 (10.5%)705 (7.1%)1405 (3.6%)0.31Thrombophilia895 (5.6%)190 (0.0%)705 (7.1%)1408 (5.7%)0.76Median (IQR) or N (%). *P*-Value of comparison of Dialysis Cases with Dialysis controls. *ADPKD* autosomal dominant polycystic kidney disease, *BMI* body mass index, *CAD* coronary artery disease, *CKD* chronic kidney disease, *CUA* calcific uremic arteriolopathy, *PAD* peripheral artery disease, *PD* peritoneal dialysis

Laboratory findings {#Sec9}
-------------------

Adjusted serum calcium, serum phosphate and normalized iPTH were significantly higher in dialyzed CUA patients than in matched dialyzed controls at lesion onset and in the six preceding months (Table [2](#Tab2){ref-type="table"}). Malnutrition preceded CUA onset, with a median albumin decrease of 2.7 g/L within the 6 months before onset and C-reactive protein (CRP) was high at both times. Table 2Laboratory parameters measured at onset of CUA and within 6 months before diagnosis (most pejorative value) in CUA and paired dialysis controlsBiological parameterRecommended range^a^NTotal CUA casesNNon dialysis casesNDialysis casesNDialysis controls*P* ValueAt onset of lesions Total serum calcium (mmol/L)2.10--2.60892.25 (2.12--2.35)192.25 (2.20--2.34)702.23 (2.11--2.38)1382.18 (2.08--2.30)0.04 Adjusted serum calcium (mmol/L)2.10--2.60882.50 (2.33--2.60)182.51 (2.43--2.68)702.48 (2.31--2.58)1362.26 (2.16--2.40)\< 0.001 Serum phosphate (mmol/L)0.8--1.5891.89 (1.50--2.34)191.98 (1.64--2.60)701.87 (1.46--2.29)1381.42 (1.13--1.87)\< 0.001 Calcium phosphate product (mmol^2^/L^2^)884.35 (3.29--5.23)184.59 (3.70--5.74)704.21 (3.19--5.22)1383.18 (2.50--4.01)\< 0.001 iPTH (pg/mL)150--60087260 (114--605)17115 (83--488)70336 (141--605)136272 (157--466)0.20 Normalized iPTH (N)2--9875.3 (2.1--11.1)172.2 (1.6--10.6)705.3 (2.5--11.1)1364.4 (2.4--8.4)0.04 iPTH outside of target range between 2 and 9 fold normal range8751 (58.6%)1714 (73.7%)7037 (52.9%)13658 (42.6%)0.16 25-Hydroxyvitamin D (ng/mL)\>  306828.5 (17.9--40.0)1324.0 (10.0--34.0)5529.9 (18.0--40.0)10134.1 (22.0--47.6)0.18 Serum Albumin (g/L)35--458830.9 (28.0--34.0)1830.4 (23.9--34.3)7031.5 (28.0--34.0)13637.0 (33.3--39.2)\< 0.01 Serum Albumin variation between diagnosis and 6 months before (g/L)80−2.7 (−5.0; 1.6)12−3.8 (−8.5; −0.5)68−2.7 (−5.0; 2.0)1341.3 (0.0; 4.0)\< 0.001 CRP (mg/L)\<  58729.0 (8.0--72.0)1734.0 (17.5--72.0)7023.5 (6.6--64.0)1354.2 (1.0--13.8)\< 0.001 Hemoglobin (g/dL)10--11.58910.4 (9.7--11.6)1910.1 (9.7--11.7)7010.6 (9.6--11.5)13611.2 (10.1--12.0)0.007Worst value within 6 months before onset of CUA Total serum calcium (mmol/L)2.10--2.60862.34 (2.17--2.47)172.33 (2.29--2.38)692.35 (2.17--2.48)1372.28 (2.20--2.37)0.30 Adjusted serum calcium (mmol/L)2.10--2.60812.54 (2.37--2.68)132.54 (2.41--2.71)682.54 (2.30--2.67)1352.43 (2.31--2.52)0.05 Serum phosphorus (mmol/L)0.8--1.5862.16 (1.75--2.57)172.00 (1.55--2.11)692.25 (1.87--2.70)1371.72 (1.44--2.15)\< 0.001 Calcium phosphate product (mmol^2^/L^2^)864.81 (4.24--6.02)174.30 (3.57--4.82)695.20 (4.44--6.50)1373.94 (3.26--4.88)\< 0.001 iPTH (pg/mL)150--60075355 (148--710)10331 (210--580)65435 (148--710)128342 (173--526)0.10 Normalized iPTH (N)2--9757.3 (3.3--12.2)106.5 (4.5--12.1)657.3 (3.3--12.2)1285.3 (2.8--8.5)0.02 iPTH outside of target value between 2 and 9 fold normal range7556 (62.9%)1015 (79.0%)6541 (63.1%)12859 (46.1%)0.01 25-Hydroxyvitamin D (ng/mL)\>  305929.0 (15.0--42.8)913.0 (9.0--25.0)5030.0 (18.0--43.0)10136.1 (20.4--48.0)0.32 Serum Albumin (g/L)35--458133.0 (29.0--37.0)1332.9 (25.0--37.5)6833.5 (29.0--37.0)13534.0 (32.0--38.0)0.049 CRP (mg/L)\<  58039.5 (14.0--79.6)1332.0 (5.9--56.0)6746.0 (14.1--79.9)13313.4 (4.5--40.2)0.004Median (IQR) or N (%). *P*-Value of comparison between dialysis cases and dialysis controls. *CRP*, C-reactive protein; *iPTH*, intact parathyroid hormone ^a^According to KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) Kidney Int Suppl 2009; 113: S1--S130. Adjusted serum calcium level was calculated using the following formula: \[serum calcium (mmol/L) + 0,025 (40-Albumin)\]

Medications at CUA lesion onset {#Sec10}
-------------------------------

Active and native vitamin D were not significantly more prescribed in CUA patients, nor statin and cinacalcet (Table [3](#Tab3){ref-type="table"}). Calcium-based phosphate binders were more frequently administered in CUA patients; 71.9% were under VKA. The median time between VKA introduction and onset of CUA was 3.2 years (IQR 1.8--6.6) and was shorter for dialyzed vs non dialyzed patients (2.6 years (IQR 1.3--5.7) vs 6.5 years (IQR 4.6--8.6)). The median time between dialysis initiation and CUA was 1.4 years (IQR 0.3--3.7). Median dialysis vintage among the control patients, estimated between the beginning of dialysis and the time of onset of CUA in the matched case, was 2.2 years (IQR 0.7--5.1). Median dialysis dose (eKt/V) was significantly lower for CUA cases compared to controls. Table 3Medications at time of diagnosis of CUA in cases and matched dialysis controlsTreatmentNTotal CUA casesNNon dialysis casesNDialysis casesNDialysis controls*P* Value25-hydroxyvitamin D8953 (59.6%)1911 (57.9%)7042 (60.0%)13789 (65.0%)0.48Active vitamin D8919 (21.4%)193 (15.8%)7016 (22.9%)13731 (22.6%)0.97Calcium-based phosphate binders8947 (52.8%)196 (31.6%)7041 (58.6%)13760 (43.8%)0.04Non calcium-based phosphate binders8947 (52.8%)194 (21.1%)7043 (61.4%)13776 (55.6%)0.41Sevelamer8937 (41.6%)194 (21.1%)7033 (47.1%)13758 (41.4%)0.43Lanthanum carbonate8912 (13.5%)191 (5.3%)7011 (15.7%)13719 (13.6%)0.68Cinacalcet8917 (19.1%)191 (5.3%)7016 (22.9%)13626 (19.1%)0.53Betablocker8954 (60.7%)1915 (79.0%)7039 (55.7%)13765 (47.5%)0.26Insulin therapy8935 (39.3%)198 (42.1%)7027 (38.6%)13834 (24.6%)0.04Vitamin K Antagonist8964 (71.9%)1911 (57.9%)7053 (75.7%)13837 (26.8%)\< 0.001Fluindione6444 (68.8%)116 (54.6%)5338 (71.7%)3718 (48.7%)Warfarin6417 (26.6%)113 (27.7%)5314 (26.4%)3716 (43.2%)Corticosteroids8910 (11.2%)192 (10.5%)708 (11.4%)13816 (11.6%)0.97Statin8946 (51.7%)199 (47.4%)7037 (52.7%)13871 (51.5%)0.85ESA8972 (80.9%)199 (47.4%)7063 (90.0%)137106 (77.4%)0.03Iron therapy8963 (70.8%)198 (42.1%)7055 (78.6%)137102 (74.4%)0.51ACEi/ARB8932 (36.0%)198 (42.1%)7024 (34.3%)13843 (31.2%)0.65Hemodialysis parameters HD6743 (64.2%)13891 (65.9%) HDF6747 (34.1%)13824 (35.8%) eKt/V621.40 (1.06--1.67)1311.53 (1.33--1.82)\< 0.001 Citrate6710 (14.3%)13820 (14.3%)1.00Median (IQR) or N (%). *P*-Value of comparison of Dialysis Cases with Dialysis controls. *ACEi/ARB* angiotensin converting enzyme inhibitor/angiotensin receptor blocker; *ESA* erythropoiesis-stimulating agent, *HD* hemodialysis, *HDF* hemodiafiltration

Clinical presentation {#Sec11}
---------------------

Fifty-nine CUA cases (66.2%) had a triggering event within the 3 months before onset. Twenty-eight cases (31.5%) had a local trauma, including physical trauma (21%), subcutaneous injection of heparin (25%) or insulin (43%) or both (11%). Thirty-five cases (39.3%) had a hypovolemia episode, including sepsis (29%), general anesthesia (11%), severe intradialytic hypotension (11%), acute heart failure (11%), severe nephrotic syndrome (9%), hemorrhage (5.7%) and multifactorial causes (23%). The same proportion of triggering event was found in dialyzed cases than in non-dialyzed cases (local trauma 30% vs 36.8%, episode of hypovolemia 38.6% vs 42.1% respectively).

Thirty-six patients (40.5%) suffered from a proximal-type CUA, while 26 (29.2%) had a distal-type, and 27 (30.3%) both proximal and distal. Lower limbs were involved in most of the patients (86.5%), especially under the knees (34.8%), while trunk lesions were found in 50.6%, mainly in the abdomen (27.0%). Upper limb lesions were present in 22.5%. A median of 5 lesions (IQR 3--6) per patient were found and were mostly ulcerative (95.5%).

CUA diagnosis {#Sec12}
-------------

The median time between onset of skin lesions and diagnosis was 46 days (IQR 24--88). When standard X-rays were performed (57.3%), calcifications were identified in arteries (29.4%), arterioles (15.7%) or both (31.4%), or vessels with extravascular calcifications (17.6%). In 24 patients (27.0%) examined by CT-scan, calcifications were identified in 75% of them. 12 out of 18 patients (66.7%) had a pathological nuclear bone scan. Transcutaneous oxygen measurement was pathological in 9 out of 11 evaluated patients. Doppler ultrasound (53 patients, 59.6%) revealed mostly medial calcification sclerosis associated with non-significant stenosis.

A skin biopsy was performed in 60 patients (67.4%), more frequently among non-dialyzed cases (79.0% vs 64.3%), with an average number of 1.6 (±0.8) biopsies per patient, and confirmed the diagnosis in 65% of cases. A specialized calcium staining was performed for 33.3% of cases, revealing calcification of arterioles (53.3%), tissues (8.3%), or both (10%). The other findings were thrombosis (50%), fibro-intimal hyperplasia (20%) and panniculitis (72%).

CUA treatments {#Sec13}
--------------

Treatments used for CUA were wound care, intravenous Sodium Thiosulfate (STS), renal replacement therapy modification and nutritional support therapy (Table [4](#Tab4){ref-type="table"}). Other treatments were discontinued, notably VKA, calcium supply and vitamin D. Median dosing of intravenous STS was 75 g per week, and the cumulative dose was higher for dialysis patients. Some treatments were scarcely used, and included, intra-lesional STS (1.1%), hyperbaric oxygen (2.3%), bisphosphonate (2.3%) and vitamin K supplementation (1.1%). Table 4Multimodal treatment strategy of CUA: initiation and modifications of treatments after CUA diagnosisTreatmentNTotal CUA casesNDialysis casesNNon dialysis casesWound care8988 (98.9%)7070 (100.0%)1918 (94.7%)Antibiotherapy8969 (77.5%)7053 (75.7%)1916 (84.2%)Discontinuation of VKA6546 (70.8%)5438 (70.4%)118 (72.7%)Discontinuation of active vitamin D2014 (70.0%)1711 (64.7%)33 (100.0%)Intravenous STS8958 (65.2%)7045 (64.3%)1913 (68.4%) STS cumulative dose (g)56488 (300--750)43525 (300--750)13375 (225--900) STS duration (week)586 (4--10)456 (4--10)135 (3--12)Renal Replacement Therapy modification8957 (64.0%) Increase of dialysis duration and/or frequency7041 (58.6%) Start of dialysis1916 (84.2%) Switch from HD to HDF7013 (18.6%) Switch from HDF to HD704 (5.7%) Use of citrate dialysate896 (6.7%)706 (8.6%)190 (0.0%)Discontinuation or lowering of oral calcium supply5331 (58.5%)4626 (56.5%)75 (71.43%)Nutritional support therapy8947 (52.8%)7035 (50.0%)1912 (63.2%)Sevelamer8942 (47.2%)7031 (44.3%)1911 (57.9%) Initiation or dose increase of Sevelamer8924 (27.0%)7015 (21.4%)199 (47.4%)Initiation or dose increase of Cinacalcet8931 (34.8%)7027 (38.6%)194 (21.1%)Discontinuation of native vitamin D5218 (34.6%)4012 (30.0%)126 (50.0%)Surgical debridement8922 (24.7%)7017 (24.3%)195 (26.3%) ≥ 2 surgical debridement899 (10.1%)708 (11.4%)191 (5.26%)Amputation8915 (16.9%)7013 (18.6%)192 (10.5%) Lanthanum carbonate8915 (16.9%)7015 (21.4%)190 (0.0%) Initiation or dose increase of Lanthanum carbonate897 (7.9%)707 (10.0%)190 (0.0%) Negative pressure wound therapy8912 (13.5%)708 (11.4%)194 (21.1%) Discontinuation of iron therapy628 (12.9%)547 (13.0%)81 (12.5%) Standard oxygen therapy8911 (12.4%)709 (12.9%)192 (10.5%) Initiation or dose increase of statin8910 (11.2%)708 (11.4%)192 (10.5%) Skin transplantation898 (9.0%)707 (10.0%)191 (5.3%)Parathyroidectomy895 (5.6%)705 (7.1%)190 (0.0%)Steroids Discontinuation or dose decrease of steroids127 (58.3%)106 (60.0%)21 (50.0%) Initiation or dose increase of steroids122 (16.7%)102 (20.0%)00 (0.0%) Local steroids treatement8912 (13.5%)709 (12.9%)193 (15.8%)Median (IQR) or N (%). *HD* hemodialysis, *HDF* hemodiafiltration, *STS* sodium thiosulfate, *VKA* vitamin K antagonist

CUA risk factors among dialyzed patients {#Sec14}
----------------------------------------

Univariate logistic regression analysis ([Table S2](#MOESM1){ref-type="media"}) revealed dialyzed CUA patients had significantly more diabetes mellitus (Odds Ratio (OR) 2.7), diabetes and/or hypertension associated nephropathy (OR 3.0), symptomatic peripheral vascular disease (OR 2.0), history of cardiac failure (OR 4.6) or of pathologic fracture (OR 2.4). They had increased adjusted serum calcium (OR 9.2), serum phosphate (OR 4.6), calcium phosphate product (OR 2.0), normalized iPTH (OR 1.1) and CRP (OR 1.4) in the 6 months prior to identification of lesions (respectively OR 2.2; 5.4; 2.0; 1.1 and 1.1). Insulin (OR 2.1) and Erythropoiesis-Stimulating Agent (OR 2.6) also increased this risk. On the contrary, dialysis dose (eKt/V) (OR 0.2) and hemoglobin level at onset of lesions (OR 0.7) were associated with lower odds.

By multivariate analysis (Table [5](#Tab5){ref-type="table"}), risk factors independently associated CUA in dialyzed patients were obesity, coronary artery disease, weight loss over the last 6 months, serum phosphate increase within 6 months before diagnosis and VKA therapy. As lower odds were associated with serum albumin increase within the 6 months before onset of lesions (OR 0.2), serum albumin decrease was also a risk factor of CUA among the dialysis cases. Table 5Multivariate logistic regression analysis of risk factors of CUA in dialysis cases compared to matched dialysis controlsParameterOR (95% CI)*p*-valueBody Mass Index, per 5 kg/m^2^ increase1.56 (1.08--2.27)0.02Loss of weight within 6 months before diagnosis, per 1 kg increment1.66 (1.22--2.26)0.001Coronary artery disease5.52 (1.07--28.65)0.04Albumin variation between diagnosis and 6 months before, per 5 g/L increment0.19 (0.05--0.70)0.01Serum phosphate (worst value within 6 months before onset of CUA), per 1 mmol/L increment9.27 (1.70--50.68)0.01Vitamin K Antagonist5.11 (1.29--20.29)0.02

CUA outcome {#Sec15}
-----------

40.4% of deaths due to calciphylaxis occurred during the first year after diagnosis and 56.2% after 5 years (Table [6](#Tab6){ref-type="table"}). Mortality of dialysis cases was significantly higher than paired hemodialysis controls (Hazard Ratio (HR) 3.4; 95% Confidence Interval (CI) 2.2--5.2; *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}). The median delay between the onset of lesions and death was 4.1 months (IQR 2.2--14.2). The main circumstance of death was in palliative care for CUA patients (49.1%). Table 6Evolution and outcome of CUA patients, compared to dialysis controlsTotal CUA cases (*N* = 89)Non dialysis cases (*N* = 19)Dialysis cases (*N* = 70)Dialysis controls (*N* = 140)Local evolution of CUA lesions Deterioration37 (41.6%)7 (36.4%)30 (42.9%) Any improvement2 (2.3%)0 (0.0%)2 (2.9%) Partial improvement17 (19.9%)5 (26.3%)12 (17.1%) Complete healing33 (37.1%)7 (36.8%)26 (37.1%)Reccurence of CUA16 (31.4%)2 (15.4%)14 (36.8%)Crude mortality rate (uncensored) At 1 year after onset of lesions36 (40.4%)8 (42.1%)28 (40.0%)18 (12.9%) At 2 years after onset of lesions46 (51.7%)10 (52.6%)36 (51.4%)25 (18.9%) At 5 years after onset of lesions50 (56.2%)10 (52.6%)40 (57.1%)44 (31.4%)Cause of death Cardiac arrest9 (17.0%)1 (10.0%)8 (18.6%)31 (49.2%) Sepsis9 (17.0%)1 (10.0%)8 (18.6%)2 (3.2%) Palliative care26 (49.1%)7 (70.0%)19 (44.2%)11 (17.5%) Stroke0 (0.0%)0 (0.0%)0 (0.0%)3 (4.8%) Cardiac failure6 (11.3%)0 (0.0%)6 (11.3%)0 (0.0%) Death secondary to CUA38 (71.7%)7 (70.0%)31 (72.1%)0 (0.0%)Fig. 2Survival among Calcific Uremic Arteriolopathy cases and the hemodialysis controls

Complete healing of CUA lesions occurred in 37.1% (Table [6](#Tab6){ref-type="table"}). The median delay between healing and diagnosis was 6.4 months (IQR 3.7--8.9). The median follow-up was respectively 6.1 (IQR 3.0--11.4) and 16.1 (IQR 8.7--36.1) months in dialysis cases and controls.

Factors predictive of survival {#Sec16}
------------------------------

Higher BMI (HR 0.79; *p* = 0.004), higher serum albumin at onset of lesions (HR 0.70; *p* \< 0.001) and VKA discontinuation (HR 0.41; *p* = 0.01) were associated with better survival in univariate analysis only ([Table S3](#MOESM1){ref-type="media"}). After removal of patients treated less than 2 weeks or with a cumulative dose below 150 g of STS, a trend to better survival was associated with STS cumulated dose and duration (HR 0.87; CI 0.77--0.97; *p* = 0.02).

By multivariate analysis, items with *p* \< 0.2 in the univariate analysis were included, except sevelamer and lanthanum carbonate treatment at diagnosis, normalized PTH, eKt/V, number of skin biopsies, STS duration, VKA discontinuation and CUA recurrence, because of missing data. Adjusted serum calcium and calcium phosphate product were removed because of linkage to serum calcium and phosphate. Thus 192 patients were included in the multivariate analysis. Finally, factors independently associated with survival were surgical debridement (HR 0.11) and antibiotherapy (HR 0.25) (Table [7](#Tab7){ref-type="table"}), whereas parathyroidectomy increased the risk of death (HR 29.5). Table 7Multivariate conditional logistic regression analysis of survival predictors among the 89 Calcific Uremic Arteriolopathy casesParameterHR (95% CI)*p*-valueHemoglobin at diagnosis, per 1 g/dL increment0.42 (0.30--0.60)\< 0.001Insulin therapy0.28 (0.12--0.65)0.003Lower limbs localization\< 0.001 Below knee VS none0.13 (0.01--1.23)0.20 Above knee VS none0.17 (0.01--2.49)0.72 Any localization VS none107.04 (16.1--713)\< 0.001Upper limbs localization\< 0.001 Below elbow VS none10.79 (2.34--49.7)0.002 Any localization VS none267.48 (23.3--3069)\< 0.001Type of CUA\< 0.001 Distal-type VS proximal-type0.04 (0.00--0.44)0.008 Proximal and distal type VS proximal type0.01 (0.00--0.13)\< 0.001 Parathyroidectomy29.53 (3.87--226)0.001 Sevelamer0.26 (0.10--0.66)0.005 Lanthanum carbonate0.04 (0.01--0.21)\< 0.001 Surgical debridement0.11 (0.04--0.28)\< 0.001 Antibiotherapy0.25 (0.08--0.73)0.01Local evolution of skin lesions\< 0.001 Partial improvement VS complete healing1.14 (0.22--5.77)0.88 Deterioration VS complete healing497.78 (79.5--3118)\< 0.001 No improvement VS complete healing112.48 (12.4--1023)\< 0.001Hazard ratio (HR) with 95% confidence interval

Discussion {#Sec17}
==========

The 89 CUA patients of our study were typically 70-year old overweight diabetic females under VKA therapy (72%). In these cases, bone mineral disease parameters were out of the recommended ranges and were associated with inflammation and malnutrition.

These patients were identified from all over western France and the informations provided by our study are the results of average clinical management of these patients and not the experience of one expert care center. By following the Hayashi criteria \[[@CR8]\], a skin biopsy was not a prerequisite in our study and confirmed diagnosis only in required clinical situations, in particular, to rule out a differential diagnosis. Because this can worsen lesions, skin biopsies are frequently avoided. Specificity is also questioned because of the frequence of extravascular calcifications in ESRD. Skin biopsies can confirm diagnosis by showing the combination of arteriolar media calcification and thrombosis that is associated with CUA \[[@CR9]\]. We think that the identified CUA cases are the reflect of complexity of CUA diagnosis in clinical practice.

The demographic data and CUA predisposing factors identified in our study were consistent with other case-control studies \[[@CR4], [@CR10]\]. Inflammation and bone mineral disease abnormalities, especially hyperphosphatemia and hyperparathyroidism, and malnutrition preceded CUA onset by months \[[@CR2], [@CR10]\]. For the first time, weight loss within the 6 months before CUA onset was identified by our study as a risk factor in dialysis patients.

The association of CUA and VKA therapy has already been reported \[[@CR4], [@CR8], [@CR11]\]. By decreasing carboxylated matrix Gla Protein (cMGP), VKA are suspected to contribute to vascular calcification and therefore promote calciphylaxis. A low level of cMGP have also been highlighted in CUA cases associated with Vitamin K deficiency \[[@CR12]\]. Besides, Warfarin could paradoxically favor thrombosis locally, by blocking protein S endothelial secretion in response to stress \[[@CR13]\]. Thrombophilia is also a known risk factor of calciphylaxis \[[@CR14], [@CR15]\] and we assume that the low prevalence of thrombophilia in our study might be due to lack of systematic screening. As Direct oral anticoagulants have no pro-thrombotic effect and given that vessel thrombosis may play a key role in calciphylaxis, they have been used to replace VKA once diagnosis of CUA is confirmed \[[@CR16], [@CR17]\]. Two retrospective studies \[[@CR16], [@CR17]\] have assessed the safety of Apixaban in CUA patients: 4 bleeding events in 20 dialysis patients were found and a lower mortality rate was demonstrated. Additional comparative studies are of course necessary.

We were surprised to identify so many non-dialyzed patients with calciphylaxis. The frontier between uremic calciphylaxis and non-uremic calciphylaxis is difficult to define. Studies on non-uremic calciphylaxis are mainly case reports and case series. Interestingly, a review on Non Nephrogenic Calciphylaxis (NNC), defined as calciphylaxis occurring in patients without impaired renal function (eGFR \> 60 mL/min/1.73m^2^), showed that VKA and obesity were the two main conditions associated with NNC \[[@CR18]\]. Mean blood mineral parameters were normal. Calciphylaxis seems to be the conjunction of multiple conditions (obesity, VKA, bone mineral disease abnormalities, uremia, inflammation) with a broad spectrum of variations. In our study, non-dialyzed CUA patients were more obese and inflammation prior CUA onset was more severe than in dialyzed CUA patients. A link between arteriolar calcification and adipocytes could explain the preferential localization of calciphylaxis in adipose tissue areas and the increased risk of calciphylaxis associated with obesity \[[@CR4], [@CR19]\]. Childhood obesity is already known to increase coronary artery calcification by middle age \[[@CR20]\]. An increase in NNC reported cases \[[@CR18], [@CR19]\] might not only be secondary to increased medical awareness of this disease, but also might be linked to the epidemic of obesity. In our study, non-dialyzed cases had the same survival as dialysis cases, whereas some studies have reported a better prognosis of NNC \[[@CR21]\].

The mortality rate was particularly high in our study. Ulcerative lesions and proximal-type CUA, known as poor prognosis factors \[[@CR2], [@CR3]\], were predominant. The prolonged diagnosis delay (46 vs 28 days in the German registry \[[@CR22]\]) could be explained by the use of ulcerative skin lesions as inclusion criteria, because non-ulcerative lesions (plaques, nodules) precede the ulcerative lesions by several days \[[@CR3]\]. This diagnosis delay could also be linked to a lack of acknowledgment of early CUA lesions, as seen in the Japanese case control study \[[@CR10]\]. The dialysis vintage, shorter among the dialyzed cases than the matched controls (1.4 vs 2.2 years) could not explain the excess of mortality in dialyzed cases. So calciphylaxis does not necessarily occur after a long dialysis vintage. This is consistent with the important number of CUA cases identified among patients with CKD stage 4--5.

The main circumstance of death in our study was palliative care (49%), in the absence of efficient therapy to treat CUA. Due to its promising treatment properties \[[@CR23], [@CR24]\], STS was frequently administered, but was only associated with a trend toward better prognosis after exclusion of patients treated less than 2 weeks. Trials are in progress to assess the real benefit of STS in CUA. As demonstrated by other studies, surgical debridement had a net impact on survival \[[@CR25]--[@CR27]\] and should be proposed more widely. Contrary to other studies \[[@CR26]\], parathyroidectomy was associated with a poorer prognosis, but given that only 5 parathyroidectomies were performed the conclusions are limited.

Conclusions {#Sec18}
===========

Our study confirms the data reported by others on CUA but showed for the first time the contribution of significant unintentional weight loss. Few therapeutic measures seem efficient. Among them, STS is commonly used, but its benefit has still to be proved. The ongoing trials are of major interest.
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**Additional file 1: Table S1.** Differential diagnosis idendified among eligible patients. **Table S2.** Univariate logistic regression analysis of risk factors of CUA in dialysis cases compared to matched dialysis controls. **Table S3.** Univariate conditional logistic regression analysis of survival predictors among Calcific Uremic Arteriolopathy cases.
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